FINOX-Biotech is a biopharmaceutical company based in Switzerland. The company was founded in 2007 and develops biosimilars and combines them with specifically designed injection technologies.
FINOX Device Technology develops injection technology for subcutaneous, intravenous or intramuscular administration of liquid medications for the Life Science Industry. The injection technologies are differentiated by simple and safe – thus compliance-promoting – handling.
The company is developing biosimilars which are positively differentiated compared to the reference product both by a particularly attractive pricing strategy and by an innovative injection technology. They try to develop biosimilars with the aim of being “first-to-market“. This ensures an advantageous position over subsequent competitor products.
Finox is focused on getting approvals in the EU and North America, followed by a global marketing. The company’s first biosimilar is an r-FSH, a recombinant human follicle-stimulating hormone (AFOLIA) and currently, the Phase III study is recruting patients in centers throughout Europe.
The product is a biosimilar version of Gonal-F from Merck Serono, which is a member of Merck KGaA group of Germany. AFOLIA will look for approval in 2012 and FINOX is currently evaluating further development candidates.
Source: Finox Biotech